India, March 4 -- BioCardia, Inc. (BCDA) shares are falling more than 23 percent on Monday morning, despite positive interim reports for its Phase III randomized trial of CardiAMP autologous cell therapy in 110 randomized patients with advanced chronic heart failure.
The shares have reached a new peak yesterday and fell from there.
Currently, shares are at $0.4380, down 22.92 percent from the previous close of $0.57 on a volume of 2,470,727.
The biotechnology company announced positive interim results from the Phase III randomized controlled trial of its CardiAMP autologous cell therapy in 110 randomized patients with advanced chronic heart failure at a mean 20-month follow-up.
Results showed reductions in heart death equivalents and MA...